공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

연속 혈당 모니터링(CGM) 시장 : 예측(2021-2026년)

Continuous Glucose Monitoring (CGM) Market - Forecasts from 2021 to 2026

리서치사 Knowledge Sourcing Intelligence
발행일 2021년 10월 상품 코드 1013786
페이지 정보 영문 106 Pages
가격
US $ 3,950 ₩ 4,730,000 PDF (Single User License)
US $ 4,550 ₩ 5,448,000 PDF (Multiple User License)
US $ 6,950 ₩ 8,322,000 PDF (Enterprise License)


연속 혈당 모니터링(CGM) 시장 : 예측(2021-2026년) Continuous Glucose Monitoring (CGM) Market - Forecasts from 2021 to 2026
발행일 : 2021년 10월 페이지 정보 : 영문 106 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

연속 혈당 모니터링(CGM) 시장은 예측기간에 27.3%의 CAGR로 성장할 전망이며, 2019년 46억 2,300만 달러에서 2026년에는 311억 200만 달러 시장 규모에 달할 것으로 예측됩니다. 시장 성장을 촉진할 것으로 예상되는 주요 요인에는 고령 인구 급증이나 당뇨병의 높은 유병률 등을 들 수 있습니다. 국제당뇨병연합에 의하면 세계의 당뇨병 환자는 2040년까지 6억 4,200만명에 달할 것으로 예측됩니다.

이것은 성인 10명 중 1명이 2040년까지 당뇨병에 걸리는 것으로 심각함을 나타내고 있습니다. 당뇨병 치료와 관리는 세계의 헬스케어 부문과 이해관계자의 주요 중점 분야로 생각됩니다. 당뇨병 증례 증가는 시장에 높은 성장성과 기회를 가져올 것으로 예상되고, 그 결과 많은 시장 진출 기업이 혁신적인 제품과 제품 라인 확장을 요구하고 있습니다.

세계의 연속 혈당 모니터링(CGM : Continuous Glucose Monitoring) 시장에 대해 조사했으며, 시장 성장 촉진요인 및 억제요인, 용도·최종 용도 업계·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 시장 정의
  • 시장 세분화

제2장 조사 방법

  • 조사 데이터
  • 가정

제3장 주요 요약

  • 조사 하이라이트

제4장 시장 역학

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • Porter's Five Forces 분석
  • 업계의 밸류체인 분석

제5장 용도별 : 연속 혈당 모니터링 시장 분석

  • 당뇨병 환자
  • 중증 환자

제6장 최종 용도 업계별 : 연속 혈당 모니터링 시장 분석

  • 병원
  • 진단 센터와 클리닉
  • 홈케어

제7장 지역별 : 연속 혈당 모니터링 시장 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 남미
  • 유럽
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 기타
  • 중동과 아프리카
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 기타

제8장 경쟁 환경과 분석

  • 주요 기업과 전략 분석
  • 신흥 기업과 시장 수익성
  • 합병, 인수, 합의 및 협업
  • 벤더의 경쟁 매트릭스

제9장 기업 개요

  • Dexcom, Inc.
  • Abbott Laboratories
  • Medtronic Pvt. Ltd.
  • GlySens
  • Medtrum Technologies, Inc.
  • Tandem Diabetes Care
  • Senseonics
  • A. Menarini Diagnostics s.r.l
  • Roche Diagnostics
  • Ypsomed AG
KSM 21.07.08

The continuous glucose monitoring market is expected to grow at a compound annual growth rate of 27.30% over the forecast period to reach a market size of US$31.102 billion in 2026, from US$4.623 billion in 2019.

Continuous glucose monitoring is used to track blood glucose levels, which is also knowns as blood sugar. Doctors and patients usually see and examine glucose levels, which helps them in making more informed and clear decisions, about some of the common activities, such as physical activity, food balance, and medicines. The market is expected to surge in the coming years, due to the increasing rate of diabetes, worldwide. Moreover, the rise of the geriatric population is also expected to play a major role in the overall market growth. Major companies have been investing a significant sum of capital into the development of novel and advanced glucose monitoring solutions, worldwide.

An increasing rate of diabetes

The market is expected to surge and grow during the forecast period, due to the rising rate of diabetes. According to the data given by the World Health Organization, the total number of persons that have been suffering from diabetes grew from 108 million in 1980 to more than 422 million in the year 2019. Moreover, diabetes has been a key cause of lower limb amputation, stroke, heart attacks, kidney failure, and blindness. In 2019, there had been approx. 1.5 million deaths were related to diabetes. Furthermore, around 2.2 million deaths were due to high blood glucose in 2012. Continuous glucose monitors are widely used by diabetic patients. The monitors help in the measurement of glucose in the fluid, inside a person's body. Dexcom Inc., a key player in real-time continuous glucose monitoring systems, announced in September 2021 that young people with type 1 diabetes would now be covered by the company's G6 continuous glucose monitoring system.

Latest Developments

There has been a surge in spending, intending to develop novel and advanced glucose monitoring solutions and monitors. Firms and corporations have been spending a significant sum of their capital on the development of innovative, high-quality, and advanced continuous glucose monitoring devices and solutions.

  • For instance, in October 2021, GraphWear, one of the promising players in the market, announced that it had raised US$20.5 million in its latest Series B funding for the development of its novel and advanced needle-free continuous glucose monitoring platform. The novel round had been led by Mayfield, with further participation from VSC Ventures, Builders VC, and MissionBio Capital. This development is expected to accelerate the market growth rate, in the coming years.
  • In October 2021, GlucoMedium announced that it had signed a novel design and development collaboration with Molex company, Philips-Medisize. The novel collaboration would focus on the creating and development of a final blueprint for high-volume production of GlucoMedium's needle-free and precise continuous glucose monitor, with the use of its patented MHD platform technology. This development will play a major role in the market growth, in the coming years.

Segmentation:

By Application

  • Diabetes Patients
  • Critical Care Patients

By End-User Industry

  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Continuous Glucose Monitoring Market Analysis, By Application

  • 5.1. Introduction
  • 5.2. Diabetes Patients
  • 5.3. Critical Care Patients

6. Continuous Glucose Monitoring Market Analysis, By End-User Industry

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Diagnostic Centers & Clinics
  • 6.4. Home Care

7. Continuous Glucose Monitoring Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. UK
    • 7.4.2. France
    • 7.4.3. Germany
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Indonesia
    • 7.6.7. Thailand
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Dexcom Inc.
  • 9.2. Abbott Laboratories
  • 9.3. Medtronic Pvt. Ltd.
  • 9.4. GlySens
  • 9.5. Medtrum Technologies Inc.
  • 9.6. Tandem Diabetes Care
  • 9.7. Senseonics
  • 9.8. A. Menarini Diagnostics s.r.l
  • 9.9. Roche Diagnostics
  • 9.10. Ypsomed AG
Back to Top
전화 문의
F A Q